RenovoRx, Inc.
- Open
- 0.99
- Day high
- 0.99
- Day low
- 0.93
- Prev close
- 0.98
- Volume
- 76K
- Mkt cap
- $44M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.9
- P/S
- 29.7
- Yield
- —
- Per share
- —
- ▲Insiders net buying $20K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions accumulating (13F)
RenovoRx, Inc. (RNXT) is a Healthcare company listed on NASDAQ. The stock is down 23% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
RenovoRx, Inc. (RNXT) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RNXT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.08 | $-0.08 | +0.0% | $563000 | +19.9% |
| Mar 30, 2026 | $-0.08 | $-0.08 | -4.6% | $238000 | -43.3% |
| Nov 13, 2025 | $-0.08 | $-0.08 | +0.0% | $266000 | -34.4% |
| Aug 14, 2025 | $-0.08 | $-0.08 | +0.0% | $422000 | +38.8% |
| May 15, 2025 | $-0.08 | $-0.08 | +0.0% | $197000 | +7.5% |
| Mar 31, 2025 | $-0.13 | $-0.12 | +7.7% | $43000 | -74.3% |
| May 10, 2024 | $-0.14 | $-0.07 | +50.0% | — | — |
| Nov 13, 2023 | $-0.30 | $-0.27 | +10.0% | — | — |
| Aug 16, 2023 | $-0.25 | $-0.22 | +12.0% | — | — |
| May 15, 2023 | $-0.25 | $-0.36 | -44.0% | — | — |
| Mar 2, 2023 | $-0.26 | $-0.23 | +11.5% | — | — |
| Nov 14, 2022 | $-0.27 | $-0.24 | +11.1% | — | — |
RNXT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 21, 2026 | VOLL MARKofficer: Chief Financial Officer | Buy | 25,000 | $0.79 |
| Apr 7, 2026 | VOLL MARKofficer: Chief Financial Officer | Grant | 80,000 | — |
| Apr 7, 2026 | Agah Ramtindirector, officer: Chief Medical Officer | Grant | 621,727 | $0.98 |
| Apr 7, 2026 | Bagai Shaundirector, officer: Chief Executive Officer | Grant | 946,107 | $0.98 |
| Apr 7, 2026 | Gentry Leesaofficer: Chief Clinical Officer | Grant | 128,550 | $0.98 |
| Mar 27, 2026 | VOLL MARKofficer: Chief Financial Officer | Grant | 12,380 | — |
| Mar 24, 2026 | VOLL MARKofficer: Chief Financial Officer | Buy | 48,600 | $1.93 |
| Mar 24, 2026 | Marton Laurencedirector | Buy | 9,720 | — |
| Mar 24, 2026 | Bagai Shaundirector, officer: Chief Executive Officer | Buy | 12,150 | $1.93 |
| Mar 24, 2026 | Bagai Shaundirector, officer: Chief Executive Officer | Buy | 24,300 | — |
| Mar 24, 2026 | Marton Laurencedirector | Buy | 4,860 | $1.93 |
| Mar 24, 2026 | VOLL MARKofficer: Chief Financial Officer | Buy | 97,200 | — |
| Jan 22, 2026 | Agah Ramtindirector, officer: Chief Medical Officer | Buy | 10,000 | $1.00 |
| Jan 5, 2026 | Agah Ramtindirector, officer: Chief Medical Officer | Buy | 9,795 | $0.86 |
| Jan 2, 2026 | Agah Ramtindirector, officer: Chief Medical Officer | Buy | 205 | $0.83 |
Source: RNXT SEC Form 4 filings, latest May 21, 2026. For informational purposes only — not investment advice.
See the full RNXT insider & 13F page →RenovoRx, Inc. company profile
Overview
RenovoRx, Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Los Altos, California. The company went public in August 2021 and focuses on developing innovative therapies for treating solid tumors, particularly pancreatic cancer. RenovoRx has developed a unique approach combining drug delivery devices with chemotherapy medications to improve treatment outcomes while reducing side effects for cancer patients.
Business
RenovoRx operates in the biotechnology sector, specifically within the field of interventional oncology, which represents a specialized area of cancer treatment that uses minimally invasive, image-guided procedures to deliver therapies directly to tumors. The company's core innovation centers around Transarterial Microperfusion (TAMP) therapy, a proprietary platform that enables targeted drug delivery to solid tumors through specialized catheters. The company's lead product candidate is RenovoGem, which consists of two components: the chemotherapy drug gemcitabine and a proprietary delivery device called RenovoCath. Gemcitabine is an established chemotherapy medication commonly used to treat various cancers, including pancreatic cancer. However, when administered systemically through traditional intravenous methods, it often causes significant side effects and may not achieve optimal concentrations at the tumor site. RenovoCath is a specialized catheter system designed to deliver chemotherapy drugs directly into the arteries that supply blood to tumors, allowing for higher local drug concentrations while minimizing systemic exposure and associated side effects. The company primarily focuses on pancreatic cancer, one of the most challenging cancers to treat with particularly poor survival rates. Locally advanced pancreatic cancer, RenovoRx's primary target indication, represents cases where the tumor cannot be surgically removed but has not yet spread to distant organs. This patient population has limited treatment options and represents a significant unmet medical need in oncology.
Revenue model
RenovoRx operates a dual revenue model combining device sales and potential future drug sales. Currently, the company generates revenue through sales of its RenovoCath delivery device to medical institutions, with Q1 2025 marking the first quarter of meaningful revenue generation at $197,000. The company has received purchase orders from over 10 medical institutions and is targeting the top 200 high-volume cancer treatment centers in the United States. The primary customers are hospitals and cancer treatment centers that perform interventional oncology procedures. These institutions purchase the RenovoCath devices for use in treating patients with locally advanced pancreatic cancer. The company estimates a potential peak U.S. annual sales opportunity of $400 million for its targeted approach. Looking forward, RenovoRx's business model will expand significantly if its Phase III clinical trial succeeds and RenovoGem receives FDA approval. This would enable the company to commercialize both the device and drug combination, potentially commanding premium pricing for the complete therapeutic solution. The company is exploring both direct sales through a small internal sales force and strategic partnerships with companies that have existing distribution channels to interventional oncologists and radiologists. Several factors could impact RenovoRx's margins and revenue potential. Positive factors include the high unmet medical need in pancreatic cancer treatment, the potential for premium pricing due to improved efficacy and reduced side effects, and the company's intellectual property protection through patents. Negative factors include the competitive landscape in oncology, regulatory risks associated with clinical trials, reimbursement challenges from insurance providers, and the significant costs associated with clinical development and commercialization in the pharmaceutical industry.
Competitive moat
RenovoRx's competitive moat is moderate and primarily based on its proprietary Transarterial Microperfusion (TAMP) technology platform and patent protection. The company has secured intellectual property rights for its catheter delivery system and treatment approach, which provides some barrier to direct competition. The specialized nature of interventional oncology and the technical expertise required to develop and manufacture precision catheter systems creates additional barriers for new entrants. However, the company's moat faces several vulnerabilities. The biotechnology and medical device industries are highly competitive, with large pharmaceutical companies and established medical device manufacturers possessing significantly greater resources for research, development, and commercialization. Major players like Boston Scientific, Medtronic, and pharmaceutical giants could potentially develop competing targeted delivery systems or acquire smaller companies with similar technologies. The company's moat strength will ultimately depend on clinical trial outcomes and regulatory approval success. If RenovoGem demonstrates superior efficacy and safety in its Phase III trial, this could establish RenovoRx as a leader in targeted pancreatic cancer therapy. However, failure to achieve primary endpoints or regulatory setbacks could quickly erode any competitive advantages. Additionally, the company's current focus on a single indication (pancreatic cancer) makes it vulnerable to competitive threats and limits diversification opportunities compared to larger pharmaceutical companies with broader portfolios.
Risks & safety
RenovoRx presents a moderate margin of safety profile typical of clinical-stage biotechnology companies, with both strengths and significant risks. • **Cash Position**: Strong liquidity with $14.6 million in cash and short-term investments as of Q1 2025, providing operational runway • **Debt Level**: Minimal debt burden with debt-to-equity ratio of 0.014, indicating low financial leverage risk • **Current Ratio**: Excellent at 9.07, demonstrating strong short-term liquidity position • **Cash Burn**: High operating cash flow burn of $3.4 million in Q1 2025, requiring careful cash management • **Revenue Generation**: Early-stage revenue of $197,000 in Q1 2025, showing initial commercialization progress • **Valuation Concerns**: Trading at premium valuations typical of clinical-stage biotech companies • **Clinical Risk**: Primary value dependent on Phase III trial success, creating binary outcome risk for investors
Recent development
Over the past few years, RenovoRx has made significant progress transitioning from a pure research and development company to early commercialization. The most critical development has been the advancement of its Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, which has shown promising interim results with median overall survival of 16 months compared to 10 months with standard chemotherapy, along with a 65% reduction in adverse events. The company achieved a major milestone by beginning revenue generation in late 2024 and Q1 2025 through RenovoCath device sales, marking its transition from a pre-revenue to revenue-generating company. This commercialization effort has expanded to over 10 medical institutions, with notable participation from prestigious centers like Johns Hopkins Medicine in the clinical trial. RenovoRx has strengthened its intellectual property position by securing additional U.S. patents for its TAMP therapy platform, providing enhanced protection for its core technology. The company has also been exploring strategic partnerships for sales distribution while building capabilities for potential direct sales to the top 200 cancer treatment centers in the United States. Management and board confidence has been demonstrated through significant insider purchases, with approximately 143,000 shares acquired, signaling strong belief in the company's prospects. The company is also exploring international expansion opportunities, including pursuing CE mark approval for European markets, though current focus remains on the U.S. market where the regulatory pathway is most advanced.
RNXT company profile · for informational purposes only — not investment advice.
Track RNXT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free